BAT appoints new Director of Research and Science

Quick Navigation

Jump to content Logo
BAT appoints new Director of Research and Science
News release

BAT has appointed Dr James Murphy, as its new Director, Research and Science, joining the Management Board and reporting to the Chief Executive.

09 May 2023

Dr Murphy will play a central role in leading BAT’s extensive research and development programmes, which supports the company’s commitment to reducing the health impact of its business by offering consumers a range of alternative reduced risk*† tobacco and nicotine products.

Dr MurphyBased at BAT’s Research & Development hub in Southampton, Dr Murphy will be leading the global Research and Science team, ensuring world-class science and best practice are applied to all aspects of BAT’s work. He will help deliver further scientific evidence that supports BAT’s New Categories products.

Jack Bowles, BAT Chief Executive, said: “James is a highly experienced, much-admired leader, with a proven track record of positively impacting our global scientific engagement with regulators, media and the external scientific community. BAT has made significant progress over recent years to advance our commitment to tobacco harm reduction and deliver our purpose of building A Better Tomorrow. James’ leadership and experience will help further accelerate that progress.”

Dr Murphy has played a significant role in the development of BAT’s New Categories since day one, having been Product Development Lead for BAT’s first vapour launches in 2013–2014. As Head of Reduced Risk Substantiation, he created and published the Group’s nine-step scientific assessment framework to assess BAT’s New Category products.

Dr Murphy brings two decades of experience and has held a number of senior roles in R&D, Operations and Marketing at BAT. He was most recently Executive Vice President, U.S. Scientific Research & Development, based at the headquarters of BAT’s U.S. business in Winston-Salem, North Carolina.

* Based on the weight of evidence and assuming a complete switch from cigarette smoking. These products are not risk free and are addictive.

† Our vapour product Vuse (including Alto, Solo, Ciro and Vibe), and certain products, including Velo, Grizzly, Kodiak, and Camel Snus, which are sold in the U.S., are subject to FDA regulation and no reduced-risk claims will be made as to these products without agency clearance.

Forward-looking statements

This release contains certain forward-looking statements, including "forward-looking" statements made within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "believe," "anticipate," "could," "may," "would," "should," "intend," "plan," "potential," "predict," "will," "expect," "estimate," "project," "positioned," "strategy," "outlook", "target" and similar expressions. These include statements regarding our customer target ambition, New Categories revenue targets and our ESG targets.

All such forward-looking statements involve estimates and assumptions that are subject to risks, uncertainties and other factors. It is believed that the expectations reflected in this release are reasonable but they may be affected by a wide range of variables that could cause actual results to differ materially from those currently anticipated. A review of the reasons why actual results and developments may differ materially from the expectations disclosed or implied within forward-looking statements can be found by referring to the information contained under the headings “Cautionary Statement” and "Group Principal Risks " in the 2021 Annual Report and Form 20-F of British American Tobacco p.l.c. (BAT).

Additional information concerning these and other factors can be found in BAT's filings with the U.S. Securities and Exchange Commission ("SEC"), including the Annual Report on Form 20-F and Current Reports on Form 6-K, which may be obtained free of charge at the SEC's website, and BAT’s Annual Reports, which may be obtained free of charge from the BAT website

Past performance is no guide to future performance and persons needing advice should consult an independent financial adviser. The forward-looking statements reflect knowledge and information available at the date of preparation of this release and BAT undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. Readers are cautioned not to place undue reliance on such forward-looking statements.



Press Office
+44 (0) 20 7845 2888 (24 hours)